AR119974A1 - Composición radiofarmacéutica concentrada, estable - Google Patents
Composición radiofarmacéutica concentrada, estableInfo
- Publication number
- AR119974A1 AR119974A1 ARP200102561A ARP200102561A AR119974A1 AR 119974 A1 AR119974 A1 AR 119974A1 AR P200102561 A ARP200102561 A AR P200102561A AR P200102561 A ARP200102561 A AR P200102561A AR 119974 A1 AR119974 A1 AR 119974A1
- Authority
- AR
- Argentina
- Prior art keywords
- radionuclide
- salts
- optionally
- pharmaceutical composition
- complex formed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción se relaciona con soluciones de complejos de radionucleidos de elevada concentración y de elevada estabilidad química, que permite su uso como producto de droga para propósitos de diagnóstico y/o terapéuticos. La estabilidad del producto de droga es lograda mediante al menos un estabilizante contra la degradación radiolítica. Se halló particularmente ventajoso el uso de dos estabilizantes introducidos durante el proceso de fabricación en diferentes etapas. Reivindicación 1: Una composición farmacéutica que comprende: (a) un complejo formado por (ai) un radionucleido, y (aii) una fracción molecular peptídica de unión antagonista al receptor del péptido liberador de gastrina ligada a un agente quelante; y; (b) al menos dos estabilizadores contra la degradación radiolítica; y (c) opcionalmente un surfactante. Reivindicación 13: Una composición farmacéutica que comprende: (a) un complejo formado por (ai) el radionucleido ¹⁷⁷Lutecio (Lu-177), y (aii) NeoB de la fórmula (1); y; (b) ácido gentísico o sales del mismo y ácido ascórbico o sales del mismo; (c) opcionalmente, Hidroxiestearato de Macrogol 15, (d) opcionalmente, al menos un otro excipiente farmacéuticamente aceptable. Reivindicación 15: Una composición farmacéutica que consiste en: (a) un complejo formado por (ai) radionucleido ¹⁷⁷Lutecio (Lu-177), y (a2) NeoB de la fórmula (1); y; (b) ácido gentísico o sales del mismo y ácido ascórbico o sales del mismo; (c) Hidroxiestearato de Macrogol 15; (d) buffer acetato; (e) agua para inyección, y (f) NaOH, (g) DTPA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19197607 | 2019-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119974A1 true AR119974A1 (es) | 2022-01-26 |
Family
ID=67981980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102561A AR119974A1 (es) | 2019-09-16 | 2020-09-15 | Composición radiofarmacéutica concentrada, estable |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220401593A1 (es) |
| EP (1) | EP4031193A1 (es) |
| JP (1) | JP2022548875A (es) |
| KR (1) | KR20220063218A (es) |
| CN (1) | CN114728088A (es) |
| AR (1) | AR119974A1 (es) |
| AU (1) | AU2020349002B2 (es) |
| CA (1) | CA3154302A1 (es) |
| IL (1) | IL291315A (es) |
| TW (1) | TW202123976A (es) |
| WO (1) | WO2021052960A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023100852A1 (ja) * | 2021-11-30 | 2023-06-08 | 日本メジフィジックス株式会社 | 安定化放射性医薬組成物 |
| CN114404619A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其制备方法和用途 |
| CN114404618A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2526556C (en) * | 2003-07-24 | 2012-09-25 | Bracco Imaging S.P.A. | Stable radiopharmaceutical compositions and methods for their preparation |
| WO2008009444A1 (en) | 2006-07-19 | 2008-01-24 | Van Dulmen, Adrianus, A. | Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide |
| EP3536347A1 (en) * | 2012-09-25 | 2019-09-11 | Advanced Accelerator Applications USA, Inc. | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer |
-
2020
- 2020-09-15 AR ARP200102561A patent/AR119974A1/es unknown
- 2020-09-15 EP EP20768373.1A patent/EP4031193A1/en active Pending
- 2020-09-15 KR KR1020227012069A patent/KR20220063218A/ko unknown
- 2020-09-15 CA CA3154302A patent/CA3154302A1/en active Pending
- 2020-09-15 US US17/753,762 patent/US20220401593A1/en active Pending
- 2020-09-15 CN CN202080079709.9A patent/CN114728088A/zh active Pending
- 2020-09-15 AU AU2020349002A patent/AU2020349002B2/en active Active
- 2020-09-15 JP JP2022516404A patent/JP2022548875A/ja active Pending
- 2020-09-15 TW TW109131644A patent/TW202123976A/zh unknown
- 2020-09-15 WO PCT/EP2020/075767 patent/WO2021052960A1/en unknown
-
2022
- 2022-03-13 IL IL291315A patent/IL291315A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021052960A1 (en) | 2021-03-25 |
| EP4031193A1 (en) | 2022-07-27 |
| AU2020349002A1 (en) | 2022-04-28 |
| US20220401593A1 (en) | 2022-12-22 |
| AU2020349002B2 (en) | 2024-05-02 |
| JP2022548875A (ja) | 2022-11-22 |
| IL291315A (en) | 2022-05-01 |
| KR20220063218A (ko) | 2022-05-17 |
| TW202123976A (zh) | 2021-07-01 |
| CN114728088A (zh) | 2022-07-08 |
| CA3154302A1 (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119974A1 (es) | Composición radiofarmacéutica concentrada, estable | |
| CL2023000167A1 (es) | Péptidos funcionalizados como agentes antivirales | |
| US20170224789A1 (en) | Stable injectable composition of bivalirudin and process for its preparation | |
| ECSP088175A (es) | Liberación sostenida de agentes antiinfecciosos | |
| GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
| AR119655A1 (es) | Soluciones de complejos de radionúclidos estables y concentradas | |
| AR084663A1 (es) | Preparados liofilizados de inhibidores de proteasomas | |
| AR062980A1 (es) | Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida | |
| BR112015012460B1 (pt) | Formulação estabilizada de pemetrexede | |
| AR082049A1 (es) | Formulaciones liquidas de rupatadina fumarato | |
| US20210196673A1 (en) | Compositions and methods for treating and preventing respiratory viral infections using green tree extract | |
| PE20220377A1 (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
| PT2777689E (pt) | Nova composição farmacêutica para o tratamento de infeções fúngicas | |
| AR029456A1 (es) | Forma triturada | |
| JP2017014153A (ja) | ペメトレキセドを含有する注射用溶液製剤 | |
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| WO2011111070A2 (en) | Novel injectable combination | |
| AU2019222876A1 (en) | Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of MPS IIIC | |
| AR069249A1 (es) | Derivado de indazol, activo en el dolor neuropatico | |
| CO6612211A2 (es) | Derivado de amida que tiene una acción hipoglucémica y/o una acción protectora de células b o pancreas | |
| EP2804597B1 (en) | Aqueous paracetamol composition for injection | |
| PE20190168A1 (es) | Complejos radiofarmaceuticos | |
| JP2019019075A (ja) | ペメトレキセド含有液状医薬組成物 | |
| ES2371340T3 (es) | Preparados líquidos acuosos y preparados líquidos acuosos fotoestables. | |
| JPWO2014119643A1 (ja) | 澄明な水性液剤 |